Amgen Inc. (AMGN.BA)
-Buenos Aires 193.55 0.00(0.00%) Apr 29
| Prev Close: | 193.55 |
|---|
| Open: | 193.55 |
|---|
| Bid: | 193.55 |
|---|
| Ask: | 193.55 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 193.55 - 193.55 |
|---|
| 52wk Range: | 38.75 - 193.55 |
|---|
| Volume: | 130 |
|---|
| Avg Vol (3m): | 0 |
|---|
| Market Cap: | 145.16B |
|---|
| P/E (ttm): | 32.76 |
|---|
| EPS (ttm): | 5.91 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in ARS.
Headlines
- Midday Glance: Biotechnology companiesAP(Tue 1:16PM EDT)
- Early Glance: Biotechnology companiesAP(Tue 10:36AM EDT)
- Final Glance: Biotechnology companiesAP(Mon, May 20)
- News Summary: Merck names ex-Amgen exec to run R&DAP(Thu, Mar 7)
- Merck replacing R&D head with former company execAP(Thu, Mar 7)
- FDA halts Amgen study after teen patient deathAP(Tue, Feb 26)
- Movers roundup: Universal Display, AmgenAP(Mon, Feb 25)
- Amgen rises on recall of Affymax anemia drugAP(Mon, Feb 25)
- Shares of Affymax plunge on recall newsAP(Mon, Feb 25)
- Southern diet, fried foods, may raise stroke riskAP(Thu, Feb 7)
- Amgen raises 2013 earnings outlook on tax creditAP(Thu, Feb 7)
- Illumina posts gain in 4Q on business unit saleAP(Mon, Jan 28)
- Amgen 4Q profit drops 16 pct. on higher spendingAP(Wed, Jan 23)
- News Summary: Amgen 4Q profit drops, costs riseAP(Wed, Jan 23)
- Earnings Preview: Amgen to report 4Q WednesdayAP(Tue, Jan 22)
Reports
- No Reports available for AMGN.BA at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 8.32 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the Uni...
View More 
0.34%